Title : [The fibroblast growth factor as a predictor of symptomatic change under combined pharmacological treatment of benign prostatic hyperplasia].

Pub. Date : 2007 Jul-Aug

PMID : 17921535






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The results of our study showed, that long-term combined medical treatment of benign prostatic hyperplasia (Finasteride 5 mg/day + Tamsulosin 0.4 mg/day) significantly decreases values of IPSS and residual urine volume (RUV) in patients, which basic level of bFGF in serum does not exceed 5.9 pg/ml. Finasteride fibroblast growth factor 2 Homo sapiens